In a joint venture, German biopharmaceutical firm BioNTech and Genevant Sciences, a genetic disorder therapeutics maker plan to develop mRNA therapy programmes targeting rare diseases with severely deficient medical attention.
Sanction of a single 300mg dose of GlaxoSmithKline’s tafenoquine in patients 16 years and above for the "radical cure" of malaria was advocated by an FDA advisory committee on finding significant evidence for its efficacy and safety.
Dr. Lionel Piroth and Dr. Marine Jacquier from the Centre Hospitalier Universitaire in Dijon reported in the New England Journal of Medicine, “A 35-year-old French woman presented to the emergency department with weakness, a feeling of electric shocks in both legs, and repeated falls; She reported that the symptoms had been progressing, and she noted that she had had difficulty riding her horse for the preceding three months.”
Despite the looming crises, Novartis will be shutting down antimicrobial research at its Novartis Institutes for Biomedical Research campus in Emeryville, California. There will be a loss of 140 jobs and the current projects will be put up for sale. This company was working on phase 2 clinical trial of LYS228 against complicated urinary tract infections and complicated intra-abdominal infections. The work on anti-dengue drugs and anti-malaria drugs (KAF156 and KAE609) were already in pipeline.
The US-based RAZOR (Randomised Open versus Robotic Cystectomy) trial revealed that robotic surgery is equally effective as traditional open surgery in order to treat bladder cancer. The study was funded by the National Cancer Institute and the discovery was published in the Lancet.
EchoNous announced that it has been granted FDA 510(k) clearance for its EchoNous Vein ultrasound device which could improve peripheral IV catheter placements. This system could provide real-time clear mages of superficial and deeper veins.
The U.S. Food and Drug Administration approved the first autonomous artificial intelligence diagnostic system, IDx-DR and the University of Iowa Healthcare has become the first healthcare organization to implement it.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.